Zentek Ltd is engaged in developing opportunities in the graphene and related nano-materials industry based on its intellectual property, patents, and Albany graphite... Show more
Zentek Ltd. operates at the intersection of advanced materials and critical minerals, leveraging proprietary graphene and graphite technologies. Its portfolio includes ZenGUARD-branded antimicrobial coatings, ZenFire intumescent gels, ZenICE icephobic coatings, and ZenArmor anti-corrosion products, alongside 100% ownership of the Albany graphite deposit in Northern Ontario. The company’s focus on high-purity graphite for specialized end markets differentiates it from broader graphite producers. Competitive positioning hinges on intellectual property protection, certification progress, and the ability to secure offtake agreements in defense and energy applications. Structural risks include scale-up challenges typical of nanotechnology commercialization and competition from established materials suppliers.
Upcoming catalysts center on Albany Graphite development milestones. Completion of the new Preliminary Economic Assessment could provide updated economics and attract strategic interest. The recently formed Strategic Graphite Partners LLC joint venture is expected to facilitate U.S. customer qualification, offtake discussions, and pursuit of government funding. Progress on product certifications through partnerships, such as with AETC for nuclear and battery markets, may unlock commercial pathways. Earnings releases will offer visibility into ZenGUARD commercialization traction and cash runway. Any shifts in the sparse analyst consensus—currently reflecting limited coverage—could emerge if these milestones are met, potentially affecting sentiment around growth catalysts and market positioning.
Zentek’s trajectory is closely tied to demand for critical minerals and advanced nanomaterials. Rising interest in domestic supply chains for defense and energy applications, supported by policy initiatives in North America, could benefit the Albany project. Broader adoption of graphene-enhanced coatings depends on performance validation and regulatory acceptance in healthcare and industrial sectors. Macro factors such as interest rates influence financing costs for development-stage projects, while inflation and commodity price volatility affect input costs and end-market demand. Geopolitical emphasis on secure, allied-sourced materials aligns with the company’s U.S. joint-venture strategy, potentially amplifying tailwinds from technology transitions in batteries and high-performance materials.
The Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. Trend Prediction Engine
Looking to 2026 and beyond, Zentek’s outlook centers on advancing the Albany Graphite Project through technical and commercial de-risking steps, including the forthcoming PEA and potential pre-feasibility work. Long-term structural drivers include expanding opportunities in high-purity graphite for nuclear, battery, and defense applications amid global efforts to secure critical mineral supplies. Cost structure evolution will depend on successful project financing and operational scaling. Margin sustainability for graphene-based products hinges on manufacturing efficiencies and market adoption rates. Technology transitions in advanced materials and regulatory developments around nanomaterials could shape competitive dynamics. Capital allocation priorities are expected to balance project advancement with commercialization of existing coatings. Consensus analyst expectations remain limited given the company’s profile, underscoring the importance of milestone delivery in shaping long-term market assumptions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsIndustry PharmaceuticalsOther
A.I.dvisor tells us that ZTEK and RVTY have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZTEK and RVTY's prices will move in lockstep.
| Ticker / NAME | Correlation To ZTEK | 1D Price Change % | ||
|---|---|---|---|---|
| ZTEK | 100% | -0.31% | ||
| RVTY - ZTEK | 25% Poorly correlated | +0.50% | ||
| NVNO - ZTEK | 25% Poorly correlated | N/A | ||
| INGN - ZTEK | 23% Poorly correlated | +0.18% | ||
| CODX - ZTEK | 23% Poorly correlated | +5.22% | ||
| OFIX - ZTEK | 23% Poorly correlated | N/A | ||
More | ||||
| Ticker / NAME | Correlation To ZTEK | 1D Price Change % |
|---|---|---|
| ZTEK | 100% | -0.31% |
| Pharmaceuticals: Other industry (52 stocks) | 4% Poorly correlated | +0.29% |
| Pharmaceuticals industry (157 stocks) | -3% Poorly correlated | +0.83% |
The 10-day RSI Oscillator for ZTEK moved out of overbought territory on August 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Momentum Indicator moved below the 0 level on August 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZTEK as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ZTEK turned negative on August 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTEK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZTEK broke above its upper Bollinger Band on July 31, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
ZTEK moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZTEK crossed bullishly above the 50-day moving average on July 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTEK advanced for three days, in of 187 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 70 cases where ZTEK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ZTEK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.165) is normal, around the industry mean (5.071). P/E Ratio (0.000) is within average values for comparable stocks, (146.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.307). Dividend Yield (0.000) settles around the average of (0.017) among similar stocks. ZTEK's P/S Ratio (1000.000) is slightly higher than the industry average of (91.060).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTEK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.